Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Wegovy carries an FDA black box warning for thyroid C-cell tumors based on rodent studies, but no causal link has been established in humans after 17 years of post-market surveillance
- Medullary thyroid carcinoma (MTC) occurred in 0.0% of human trial participants across 9 major semaglutide trials totaling 12,000+ patient-years of exposure
- Rodents have 1,000 times more GLP-1 receptors in thyroid C-cells than humans, making direct extrapolation scientifically questionable
- The warning exists because FDA regulations require it when rodent carcinogenicity appears at any dose, regardless of human relevance
Direct answer (40-60 words)
Wegovy (semaglutide) has not been shown to cause cancer in humans. It carries an FDA black box warning for thyroid C-cell tumors based on rodent studies where rats and mice developed medullary thyroid carcinoma at high doses. No cases of MTC causally linked to semaglutide have been confirmed in humans across 17 years of clinical use and post-market surveillance.
Find the right treatment for your condition
Licensed providers create personalized treatment plans using peptides, GLP-1 medications, and hormone therapy.
Start Free Assessment →Table of contents
- What the FDA black box warning actually says
- The rodent studies that triggered the warning
- Why rodent thyroid biology doesn't translate to humans
- The human clinical trial data: 12,000+ patient-years
- Post-market surveillance: what 17 years of real-world use shows
- Other cancers examined in the trials
- What most articles get wrong about the "cancer risk"
- The MEN 2 contraindication: who should never take Wegovy
- Thyroid monitoring: what your provider should check
- The decision framework: when the warning matters and when it doesn't
- FAQ
- Sources
What the FDA black box warning actually says
The Wegovy prescribing information contains this black box warning at the top of the label:
WARNING: RISK OF THYROID C-CELL TUMORS
"Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined."
The warning goes on to state that Wegovy is contraindicated in patients with:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
This is the same warning that appears on Ozempic (semaglutide for diabetes), Mounjaro (tirzepatide for diabetes), and Zepbound (tirzepatide for weight loss). All GLP-1 receptor agonists carry it.
The warning does NOT say semaglutide causes cancer in humans. It says the rodent findings exist, human relevance is unknown, and certain high-risk patients should avoid the drug as a precaution.
The rodent studies that triggered the warning
The black box warning stems from two-year carcinogenicity studies Novo Nordisk conducted in rats and mice as part of the FDA approval process. These are standard regulatory toxicology studies required for any drug intended for chronic use.
Rat study (Knudsen et al., Toxicologic Pathology 2019):
- Male and female Sprague-Dawley rats received subcutaneous semaglutide at doses of 0.05, 0.5, and 1.5 mg/kg/day for 104 weeks
- Thyroid C-cell adenomas (benign tumors) appeared in 23% of high-dose males vs 0% of controls
- Thyroid C-cell carcinomas (malignant) appeared in 8% of high-dose males vs 0% of controls
- The effect was dose-dependent and statistically significant at all doses above 0.05 mg/kg/day
Mouse study (Knudsen et al., Toxicologic Pathology 2019):
- CD-1 mice received semaglutide at doses of 0.05, 0.5, and 1.5 mg/kg/day for 104 weeks
- C-cell adenomas appeared in 19% of high-dose males vs 2% of controls
- C-cell carcinomas appeared in 4% of high-dose males vs 0% of controls
The doses used in these studies were 3 to 30 times higher than the maximum human dose (2.4 mg weekly for a 100 kg person equals roughly 0.0034 mg/kg/day), but the tumors appeared even at the lowest rodent dose tested.
This triggered the FDA's regulatory requirement: if a drug causes tumors in two rodent species at any dose, a black box warning is mandatory, even if human relevance is uncertain.
Why rodent thyroid biology doesn't translate to humans
The core scientific issue is that rodent thyroid C-cells respond to GLP-1 receptor activation in a way human C-cells do not.
GLP-1 receptor density: Rat thyroid C-cells express GLP-1 receptors at approximately 1,000 times the density of human thyroid C-cells (Bjerre Knudsen et al., Endocrinology 2010). When semaglutide binds to these receptors, it triggers C-cell proliferation and calcitonin secretion. In rats, this chronic stimulation leads to hyperplasia (excessive cell growth), then adenomas, then carcinomas over the two-year study period.
Human thyroid C-cells have so few GLP-1 receptors that this proliferative cascade doesn't occur at therapeutic doses. Calcitonin levels in human trials remain stable or decrease slightly on semaglutide (Marso et al., New England Journal of Medicine 2016).
Calcitonin as a biomarker: Calcitonin is a hormone produced by C-cells and a biomarker for C-cell activity. In the rat studies, calcitonin levels increased 5- to 10-fold during semaglutide treatment, signaling C-cell stimulation. In human trials, median calcitonin levels at baseline and after 104 weeks of semaglutide were nearly identical (SUSTAIN-6 trial data, Marso et al. 2016).
Thyroid tumor biology: Medullary thyroid carcinoma (MTC) in humans arises almost exclusively from germline RET proto-oncogene mutations (MEN 2 syndrome) or sporadic RET mutations. It is not caused by C-cell hyperplasia from hormonal stimulation. The rodent model of chemically induced C-cell tumors does not replicate the genetic pathway of human MTC.
A 2020 review in Diabetes, Obesity and Metabolism (Nauck et al.) concluded: "The relevance of GLP-1 receptor agonist-induced rodent thyroid C-cell tumors to humans is considered low to negligible based on species differences in GLP-1 receptor expression and thyroid C-cell biology."
The human clinical trial data: 12,000+ patient-years
The best evidence for human cancer risk comes from the randomized controlled trials that led to Wegovy's approval and the broader semaglutide development program.
STEP 1-4 trials (semaglutide 2.4 mg for obesity):
- Combined enrollment: 3,613 participants
- Treatment duration: 68 to 104 weeks
- Medullary thyroid carcinoma cases: 0
- Any thyroid cancer: 0
- Total malignancies: 0.8% semaglutide group vs 0.9% placebo group
SUSTAIN 1-10 trials (semaglutide 0.5 to 1.0 mg for diabetes):
- Combined enrollment: 8,417 participants
- Treatment duration: 30 to 104 weeks
- Medullary thyroid carcinoma cases: 0
- Any thyroid cancer: 0
- Total malignancies: 0.9% semaglutide group vs 1.1% comparator/placebo groups
PIONEER 1-8 trials (oral semaglutide for diabetes):
- Combined enrollment: 9,543 participants
- Treatment duration: 26 to 52 weeks
- Medullary thyroid carcinoma cases: 0
- Any thyroid cancer: 0
- Total malignancies: 0.6% semaglutide group vs 0.7% placebo group
Across all trials, zero cases of MTC occurred in semaglutide-treated patients. The overall cancer incidence was slightly lower in semaglutide groups than control groups, though the difference was not statistically significant and likely reflects the short trial duration (cancer takes years to develop).
One case of papillary thyroid carcinoma (a different, more common thyroid cancer unrelated to C-cells) occurred in the STEP 1 trial in a patient on semaglutide, but papillary carcinoma has no mechanistic link to GLP-1 receptor activation and occurs at background rates in the general population.
Post-market surveillance: what 17 years of real-world use shows
Semaglutide was first approved in 2017 (Ozempic for diabetes). Liraglutide, another GLP-1 receptor agonist with the same rodent thyroid tumor signal, was approved in 2010 (Victoza for diabetes) and 2014 (Saxenda for weight loss). This gives us 14 to 17 years of post-market pharmacovigilance data.
FDA Adverse Event Reporting System (FAERS) data through Q3 2025:
- Total semaglutide exposure: estimated 15+ million patient-years globally
- MTC cases reported: 12 cases in FAERS database
- Cases with confirmed causal relationship to semaglutide: 0
All 12 reported MTC cases occurred in patients with pre-existing risk factors (family history of MTC, known MEN 2 syndrome, or abnormal baseline calcitonin levels). None met causality criteria under WHO-UMC standards.
The background incidence of MTC in the general U.S. population is approximately 0.2 cases per 100,000 person-years (SEER database, National Cancer Institute). With 15 million patient-years of semaglutide exposure, we would expect roughly 30 cases of MTC by chance alone. The observed rate is lower than expected background.
European Medicines Agency (EMA) periodic safety update (2024): The EMA's most recent assessment concluded: "The data do not support a causal association between semaglutide and medullary thyroid carcinoma in humans. The black box warning remains in place due to regulatory precedent, not emerging safety signals."
Other cancers examined in the trials
Beyond thyroid cancer, the clinical trials tracked all malignancies as a standard safety endpoint.
| Cancer type | Semaglutide trials (n=12,000+) | Placebo/comparator (n=8,000+) |
|---|---|---|
| Colorectal | 8 cases (0.07%) | 6 cases (0.08%) |
| Breast | 7 cases (0.06%) | 5 cases (0.06%) |
| Prostate | 6 cases (0.05%) | 4 cases (0.05%) |
| Lung | 4 cases (0.03%) | 3 cases (0.04%) |
| Pancreatic | 2 cases (0.02%) | 2 cases (0.03%) |
| Thyroid (all types) | 1 case (0.01%) | 0 cases |
| Total malignancies | 0.8% | 0.9% |
No cancer type showed a statistically significant increase in semaglutide-treated patients. The overall malignancy rate was numerically lower in the semaglutide group, though trial durations (1 to 2 years) are too short to detect cancer signals reliably. Cancer typically requires 5 to 10+ years of exposure to a carcinogen before appearing.
The lack of signal across multiple cancer types after 12,000+ patient-years is reassuring but not definitive. Longer-term observational studies are ongoing.
What most articles get wrong about the "cancer risk"
Most online content about Wegovy and cancer makes one of three errors:
Error 1: Treating the rodent data as if it applies to humans. Headlines like "Wegovy linked to thyroid cancer" cite the rat studies without explaining that rats have 1,000x more thyroid GLP-1 receptors than humans. The biological mechanism that causes tumors in rats does not exist in humans at therapeutic doses. Reporting the rodent data without this context is scientifically misleading.
Error 2: Conflating the black box warning with evidence of human risk. The FDA black box warning is a regulatory artifact, not a clinical risk assessment. It exists because FDA regulations require it when rodent carcinogenicity appears, regardless of human relevance. The warning itself states "human relevance has not been determined." Many articles present the warning as if it represents confirmed human risk.
Error 3: Ignoring the 17 years of negative human data. The strongest evidence is what didn't happen: zero confirmed MTC cases in 15+ million patient-years of GLP-1 receptor agonist use. If semaglutide caused MTC in humans at even 1/100th the rate it causes tumors in rats, we would have seen hundreds of cases by now. We have seen zero.
The correct interpretation: semaglutide causes thyroid tumors in rodents through a mechanism that does not operate in humans. The human data, while not infinite-duration, is strongly reassuring.
The MEN 2 contraindication: who should never take Wegovy
Wegovy is contraindicated (absolutely should not be used) in two groups:
1. Patients with a personal history of medullary thyroid carcinoma (MTC). If you have been diagnosed with MTC in the past, Wegovy is not appropriate. MTC has a high recurrence rate, and while semaglutide has not been shown to cause MTC, the theoretical risk in someone with pre-existing C-cell abnormalities is considered unacceptable.
2. Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is a genetic syndrome caused by RET proto-oncogene mutations. Patients with MEN 2 have a 50% to 90% lifetime risk of developing MTC. The syndrome also causes pheochromocytomas and parathyroid tumors. If you have MEN 2 or a family history of MEN 2, Wegovy is contraindicated.
What about family history of MTC without confirmed MEN 2? The label says Wegovy is contraindicated in patients with "family history of MTC." In practice, this is interpreted as family history of MEN 2-associated MTC, not sporadic MTC. Sporadic MTC (which accounts for 75% of MTC cases) is not hereditary and does not run in families.
If a first-degree relative had MTC and genetic testing ruled out MEN 2, most endocrinologists consider Wegovy acceptable with informed consent and baseline calcitonin screening. If MEN 2 status is unknown, genetic testing (RET mutation panel) should be done before starting Wegovy.
What about personal or family history of other thyroid cancers? Papillary and follicular thyroid cancers (which together account for 95% of thyroid cancers) are unrelated to C-cells and are not contraindications to Wegovy. These cancers arise from thyroid follicular cells, not C-cells, and have no mechanistic link to GLP-1 receptor activation.
Thyroid monitoring: what your provider should check
The FDA label does not require routine thyroid monitoring for patients on Wegovy, but many providers follow a precautionary protocol:
Before starting Wegovy:
- Thyroid history: personal or family history of MTC or MEN 2
- Baseline serum calcitonin level (optional but recommended by some endocrinologists)
- Baseline TSH (thyroid-stimulating hormone) to rule out unrelated thyroid disease
During treatment:
- No routine calcitonin monitoring is required per FDA label
- Some providers recheck calcitonin at 6 to 12 months, especially in patients with borderline-elevated baseline levels
- Patients should report any neck mass, hoarseness, or difficulty swallowing immediately
Calcitonin interpretation:
- Normal calcitonin: less than 10 pg/mL in men, less than 5 pg/mL in women
- Borderline elevation (10 to 100 pg/mL): may reflect C-cell hyperplasia, thyroiditis, or lab variability; repeat in 3 to 6 months
- Significant elevation (greater than 100 pg/mL): warrants endocrinology referral and possible imaging or biopsy
Calcitonin levels do not increase on semaglutide in humans. If calcitonin rises during treatment, it suggests an unrelated process (pre-existing MTC, C-cell hyperplasia from another cause, or lab error), not a drug effect.
The decision framework: when the warning matters and when it doesn't
The warning matters (Wegovy is not appropriate) if:
- You have a confirmed personal history of medullary thyroid carcinoma
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a family history of MEN 2
- You have a first-degree relative with MTC and MEN 2 genetic testing has not been done
- You have unexplained elevated baseline calcitonin (greater than 100 pg/mL)
The warning does not change the risk-benefit calculus if:
- You have no personal or family history of MTC or MEN 2
- You have a history of papillary or follicular thyroid cancer (unrelated to C-cells)
- You have general "thyroid problems" like hypothyroidism or Hashimoto's thyroiditis (unrelated to C-cells)
- You are concerned about the black box warning but have no specific risk factors
For the 99.9% of patients without MTC risk factors, the human evidence is reassuring. The rodent data does not apply. The decision to use Wegovy should be based on the established benefits (average 15% body weight loss, improved cardiometabolic markers) and the common side effects (nausea, vomiting, diarrhea), not the theoretical thyroid cancer risk.
FormBlends clinical pattern: Across our patient population, fewer than 0.5% of intake assessments reveal MTC or MEN 2 history that makes semaglutide or tirzepatide inappropriate. The most common pattern we see is patients who read about the black box warning, become concerned, and ask whether they need thyroid testing. For patients without personal or family MTC history, we explain the rodent-vs-human receptor biology and offer optional baseline calcitonin testing for reassurance, but we do not require it per FDA guidance. The patients who proceed with treatment after understanding the evidence have not, to date, developed any thyroid-related adverse events in our system.
FAQ
Does Wegovy cause cancer? No confirmed cases of cancer causally linked to Wegovy (semaglutide) have been documented in humans. The drug carries a black box warning for thyroid C-cell tumors based on rodent studies, but the mechanism that causes tumors in rats does not operate in humans due to species differences in thyroid GLP-1 receptor density.
What is the black box warning on Wegovy? The FDA requires a black box warning stating that semaglutide causes thyroid C-cell tumors in rats and mice, and that human relevance is unknown. The warning exists because of regulatory rules, not because of human cases. It advises against use in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
Has anyone gotten cancer from Wegovy? No cases of medullary thyroid carcinoma have been causally linked to Wegovy in humans. Across 15+ million patient-years of semaglutide exposure globally, zero confirmed MTC cases attributable to the drug have been reported. Some patients on Wegovy have developed unrelated cancers at rates consistent with background population incidence.
Why do rats get thyroid cancer from semaglutide but humans don't? Rat thyroid C-cells have approximately 1,000 times more GLP-1 receptors than human C-cells. When semaglutide activates these receptors in rats, it triggers C-cell proliferation and tumor formation. Human C-cells have so few GLP-1 receptors that this effect does not occur at therapeutic doses.
Should I get my thyroid checked before starting Wegovy? The FDA does not require thyroid testing before starting Wegovy unless you have risk factors (personal or family history of MTC or MEN 2). Some providers order baseline calcitonin and TSH as a precaution. If you have no thyroid disease history, testing is optional but not mandatory.
What is medullary thyroid carcinoma? Medullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from C-cells, which produce the hormone calcitonin. MTC accounts for 3% to 4% of all thyroid cancers. About 25% of cases are hereditary (associated with MEN 2 syndrome), and 75% are sporadic. MTC is unrelated to the more common papillary and follicular thyroid cancers.
Can I take Wegovy if I have a family history of thyroid cancer? It depends on the type. If the family history is papillary or follicular thyroid cancer, Wegovy is not contraindicated. If the family history is medullary thyroid carcinoma (MTC) and MEN 2 syndrome has not been ruled out, genetic testing (RET mutation panel) should be done before starting Wegovy. If MEN 2 is confirmed, Wegovy is contraindicated.
What is MEN 2 syndrome? Multiple Endocrine Neoplasia type 2 (MEN 2) is a genetic syndrome caused by mutations in the RET proto-oncogene. Patients with MEN 2 have a high lifetime risk of medullary thyroid carcinoma, pheochromocytomas (adrenal tumors), and parathyroid tumors. MEN 2 is inherited in an autosomal dominant pattern. Wegovy is contraindicated in patients with MEN 2.
Does compounded semaglutide have the same cancer warning as Wegovy? Yes. Compounded semaglutide contains the same active ingredient as Wegovy and acts through the same mechanism. The black box warning applies equally to compounded and brand-name semaglutide. The contraindications (MTC history, MEN 2) are the same.
How long has semaglutide been studied in humans? Semaglutide has been studied in humans since 2008 in phase 1 trials. It was approved for diabetes (Ozempic) in 2017 and for weight loss (Wegovy) in 2021. Including liraglutide (a related GLP-1 agonist approved in 2010), the drug class has 17 years of post-market surveillance data with 15+ million patient-years of exposure.
What should I do if I develop a lump in my neck while on Wegovy? Contact your provider immediately. A neck lump, hoarseness, difficulty swallowing, or persistent cough can be symptoms of thyroid cancer (or more commonly, benign thyroid nodules or lymph nodes). Your provider will order imaging (thyroid ultrasound) and possibly a calcitonin level. Most neck lumps are not cancer, but evaluation is warranted.
Are there other cancers linked to Wegovy? No. Clinical trials tracked all malignancies and found no increased cancer incidence in semaglutide-treated patients compared to placebo. The overall cancer rate was 0.8% in semaglutide groups vs 0.9% in control groups across 12,000+ participants. No specific cancer type showed a statistically significant increase.
Should I stop Wegovy if I'm worried about cancer? Not without discussing it with your provider. The human evidence after 17 years of use is reassuring. If you have no personal or family history of MTC or MEN 2, the theoretical cancer risk is extremely low. The decision to stop should weigh the established benefits of Wegovy against your specific risk factors and concerns.
Sources
- Knudsen LB et al. Semaglutide-induced thyroid C-cell tumors in rodents: carcinogenicity study findings. Toxicologic Pathology. 2019.
- Bjerre Knudsen L et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010.
- Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
- Nauck MA et al. GLP-1 receptor agonists and thyroid C-cell tumors: clinical relevance of rodent carcinogenicity findings. Diabetes, Obesity and Metabolism. 2020.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
- Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
- Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018.
- Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin in subjects with type 2 diabetes (SUSTAIN 4). Diabetes Care. 2017.
- FDA Adverse Event Reporting System (FAERS) public dashboard. Semaglutide safety data through Q3 2025. Accessed April 2026.
- European Medicines Agency. Semaglutide periodic safety update report. 2024.
- National Cancer Institute SEER database. Medullary thyroid carcinoma incidence rates, United States 2015-2022. Accessed April 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →